Edwards Lifesciences Corporation (EW) VP Larry L. Wood Sells 18,960 Shares
Edwards Lifesciences Corporation (NYSE:EW) VP Larry L. Wood sold 18,960 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $104.76, for a total value of $1,986,249.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Larry L. Wood also recently made the following trade(s):
- On Friday, September 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $112.58, for a total value of $2,134,516.80.
- On Wednesday, August 30th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $111.81, for a total value of $2,119,917.60.
Shares of Edwards Lifesciences Corporation (EW) traded up $2.12 during trading hours on Friday, hitting $107.10. The stock had a trading volume of 954,400 shares, compared to its average volume of 1,638,442. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.49 and a quick ratio of 2.76. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45. The firm has a market capitalization of $22,660.00, a price-to-earnings ratio of 29.08, a price-to-earnings-growth ratio of 1.88 and a beta of 0.46.
Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The firm had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same period in the previous year, the company earned $0.68 earnings per share. Edwards Lifesciences Corporation’s revenue for the quarter was up 11.1% compared to the same quarter last year. research analysts anticipate that Edwards Lifesciences Corporation will post 3.75 EPS for the current year.
EW has been the topic of several research reports. Stifel Nicolaus restated a “buy” rating and set a $130.00 price target (up from $118.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Bank of America Corporation boosted their price target on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. Jefferies Group LLC boosted their price target on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the stock a “buy” rating in a report on Thursday, July 27th. Canaccord Genuity reiterated a “buy” rating and issued a $155.00 target price (up from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $130.00 target price on shares of Edwards Lifesciences Corporation in a report on Friday, July 28th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $125.17.
Large investors have recently modified their holdings of the company. ETF Managers Group LLC acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter worth approximately $112,000. Shine Investment Advisory Services Inc. purchased a new stake in Edwards Lifesciences Corporation in the 2nd quarter valued at $126,000. Cornerstone Advisors Inc. raised its position in Edwards Lifesciences Corporation by 25.1% in the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after buying an additional 219 shares during the last quarter. Alexandria Capital LLC raised its position in Edwards Lifesciences Corporation by 1.7% in the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after buying an additional 19 shares during the last quarter. Finally, MPS Loria Financial Planners LLC purchased a new stake in Edwards Lifesciences Corporation in the 2nd quarter valued at $140,000. 82.17% of the stock is currently owned by institutional investors.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.